Last edition
News about "MS Pharma "
Formycon, MS Pharma Ink MENA Deal for Keytruda Biosimilar FYB206
Formycon has signed an exclusive commercialisation agreement with MS Pharma for its Keytruda biosimilar candidate FYB206 in the MENA region. The deal includes an upfront payment, milestone-based fees, and a significant share of regional gross profits generated in the region.
MS Pharma | 05/12/2025 | By Dineshwori
Polpharma Biologics Partners with MS Pharma to Commercialize Biosimilars in MENA Region
Polpharma Biologics S.A., a biotechnology company specializing in the development and manufacturing of biosimilars, has entered into licensing agreements with MS Pharma, a leading biosimilar producer and distributor in the Middle East and North Africa (MENA) region.
MS Pharma | 03/09/2025 | By Darshana | 187
MS Pharma Sets Up MENA's First Biologics Manufacturing Hub in Saudi Arabia
MS Pharma has inaugurated the Middle East’s first biologics manufacturing facility in Saudi Arabia, a USD 50 million GMP-approved plant that establishes the company as a regional hub for advanced biopharmaceutical production aligned with Vision 2030.
MS Pharma | 28/08/2025 | By Mrinmoy Dey | 147
Kashiv Biosciences, MS Pharma Partner to Commercialise Xolair Biosimilar in MENA Region
Kashiv BioSciences and MS Pharma have entered into an exclusive licensing and supply agreement for the commercialization of ADL-018, Kashiv’s biosimilar candidate to XOLAIR (bOmalizumab) in the Middle East and North Africa (MENA) region.
MS Pharma | 07/08/2025 | By Dineshwori | 192
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy